Grąt Karolina, Grąt Michał, Rowiński Olgierd
Second Department of Clinical Radiology, Medical University of Warsaw, 02-097 Warsaw, Poland.
Department of General, Transplant and Liver Surgery, Medical University of Warsaw, 02-097 Warsaw, Poland.
Biomedicines. 2020 Aug 21;8(9):298. doi: 10.3390/biomedicines8090298.
Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are becoming some of the major health problems in well-developed countries, together with the increasing prevalence of obesity, metabolic syndrome, and all of their systemic complications. As the future prognoses are even more disturbing and point toward further increase in population affected with NAFLD/NASH, there is an urgent need for widely available and reliable diagnostic methods. Consensus on a non-invasive, accurate diagnostic modality for the use in ongoing clinical trials is also required, particularly considering a current lack of any registered drug for the treatment of NAFLD/NASH. The aim of this narrative review was to present current information on methods used to assess liver steatosis and fibrosis. There are several imaging modalities for the assessment of hepatic steatosis ranging from simple density analysis by computed tomography or conventional B-mode ultrasound to magnetic resonance spectroscopy (MRS), magnetic resonance imaging proton density fat fraction (MRI-PDFF) or controlled attenuation parameter (CAP). Fibrosis stage can be assessed by magnetic resonance elastography (MRE) or different ultrasound-based techniques: transient elastography (TE), shear-wave elastography (SWE) and acoustic radiation force impulse (ARFI). Although all of these methods have been validated against liver biopsy as the reference standard and provided good accuracy, the MRS and MRI-PDFF currently outperform other methods in terms of diagnosis of steatosis, and MRE in terms of evaluation of fibrosis.
非酒精性脂肪性肝病(NAFLD)和非酒精性脂肪性肝炎(NASH)正成为发达国家的一些主要健康问题,与此同时,肥胖、代谢综合征及其所有全身并发症的患病率也在不断上升。由于未来的预后更令人担忧,且表明受NAFLD/NASH影响的人群将进一步增加,因此迫切需要广泛可用且可靠的诊断方法。对于正在进行的临床试验中使用的非侵入性、准确的诊断方式也需要达成共识,特别是考虑到目前缺乏任何用于治疗NAFLD/NASH的注册药物。本叙述性综述的目的是介绍目前用于评估肝脏脂肪变性和纤维化的方法的相关信息。有几种成像方式可用于评估肝脏脂肪变性,从计算机断层扫描或传统B型超声的简单密度分析到磁共振波谱(MRS)、磁共振成像质子密度脂肪分数(MRI-PDFF)或受控衰减参数(CAP)。纤维化阶段可通过磁共振弹性成像(MRE)或不同的基于超声的技术进行评估:瞬时弹性成像(TE)、剪切波弹性成像(SWE)和声辐射力脉冲(ARFI)。尽管所有这些方法均已以肝活检作为参考标准进行了验证,并具有良好的准确性,但目前MRS和MRI-PDFF在脂肪变性诊断方面优于其他方法,而MRE在纤维化评估方面表现更佳。